facebook button Tyme-88-Panc: SM-88 as Third Line Therapy
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Tyme-88-Panc: SM-88 as Third Line Therapy

Sponsor: Tyme, Inc.

Tyme-88-Panc: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred

Eligible patients will have been treated with two prior lines of therapy for metastatic pancreatic cancer including one gemcitabine-based regimen and one 5-FU-based regimen.

For more information contact the research department at 631-675-5075